Cue Biopharma

CUE

Market cap $146M

CUE Hedge Fund Activity: Q1 2026 in Review

55 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2026, worth a combined $4.95M — down 26% from $6.66M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CUE positions and 5 closed out — a net gain of 10 holders — while 4 added to existing stakes and 9 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $81.3K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $215K sold.

• 55 institutional investors held Cue Biopharma (CUE) as of Q1 2026, up from 47 in Q4 2025.
• Funds reported $4.95M of Cue Biopharma stock for Q1 2026, down 26% quarter-over-quarter.
• 15 funds opened new Cue Biopharma positions in Q1 2026 and 5 closed out, a net change of +10 holders.
• The largest Cue Biopharma buyer in Q1 2026 was Geode Capital Management, an estimated $81.3K added.
• The largest Cue Biopharma seller in Q1 2026 was Boothbay Fund Management, an estimated $215K sold.

Based on aggregated 13F filings for Q1 2026.